Metastatic uveal melanoma, which affects the eye, has no approved medicines to date. Credit: Vanessa Bumbeers on Unsplash.

Biotech company InxMed has dosed the first patient in its Phase Ib trial evaluating IN10018 as a monotherapy and combination therapy in patients with metastatic uveal melanoma and NRAS mutant metastatic melanoma in the US.

The open-label trial will evaluate the safety, tolerability, PK and anti-tumour activities of IN10018 as a monotherapy and in combination with Roche’s MEK inhibitor Cobimetinib in the subjects.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will include six study sites in the US and three study sites in Australia.

Formerly known as BI853520, IN10018 is a potent and selective ATP-competitive focal adhesion kinase (FAK) small molecule inhibitor.

The drug is currently under clinical development stage in the US, Australia, and China.

InxMed chairman and CEO Dr Zaiqi Wang said: “We feel very excited about the dosing of (the) first patient of IN10018 in the US and fortunate to work with leading experts from both US and Australia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We hope that IN10018, alone or in combination with MEK inhibitor, is able to offer a new approach that improves therapeutic outcomes for the patients with deadly uveal melanoma or advanced, NRAS-mutant melanoma.”

Early clinical data of IN10018 has demonstrated a favourable safety profile and promising efficacy signals against a number of tumour types.

In a number of preclinical studies, the drug showed an anti-tumour effect against both uveal melanoma and NRAS mutant metastatic melanoma.

Such studies have also observed synergistic efficacy between IN10018 and MEK inhibitor.

Uveal melanoma is considered the most common type of intraocular cancer. The condition is said to exhibit a very dismal prognosis once it metastasises. Metastatic uveal melanoma currently has no approved medicines.